STOCK TITAN

SpyGlass Pharma: Vensana Capital I distributes 331K shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. (SGP) is the issuer in an amendment reporting that Vensana Capital I, L.P. made a 331,036-share pro rata distribution on November 16, 2026, to Vensana Capital I GP, LLC and its limited partners without additional consideration. Vensana Capital I GP, LLC then made a pro rata distribution of 8,634 shares it received to its members, also without additional consideration.

The cover pages separately report beneficial ownership of 2,979,595 shares for Vensana Capital I GP, LLC; 2,979,583 for Vensana Capital I, L.P.; 2,989,621 for Kirk Nielsen, a member of SGP’s board; and 2,981,249 for Peter Justin Klein, a managing director of the general partner. Each is listed as 8.9% of the class, based on 33,461,450 shares outstanding as of November 2, 2026. These totals overlap: Vensana I’s shares are also attributed as shared voting and dispositive power to its general partner and the managing directors.

Filing Explained

This amendment adds that Vensana’s reporting persons reserve the ability to acquire or dispose of shares and intend to review their investment; that states future flexibility, not a committed purchase or sale.

Vensana I distribution 331,036 shares Distributed pro rata to Vensana Capital I GP, LLC and its limited partners on November 16, 2026, without additional consideration.
Distribution by Vensana Capital I GP, LLC 8,634 shares Distributed pro rata to its members from shares received from Vensana I, without additional consideration.
Shares outstanding 33,461,450 shares As of November 2, 2026; basis cited for the reported ownership percentages.
Reported ownership percentage 8.9% Listed for each of the four reporting persons.
Vensana Capital I GP, LLC beneficial ownership 2,979,595 shares Amount reported by the general partner.
Vensana Capital I, L.P. beneficial ownership 2,979,583 shares Amount reported by the limited partnership.
Kirk Nielsen beneficial ownership 2,989,621 shares Amount reported by the SGP board member; includes shares attributed through Vensana I and other holdings described in the amendment.
Peter Justin Klein beneficial ownership 2,981,249 shares Amount reported by the managing director of Vensana Capital I GP, LLC; includes shares attributed through Vensana I.
pro rata distribution financial
"a pro rata distribution without additional consideration"
A pro rata distribution is when a company or organization shares out money, assets, or benefits evenly among all eligible people based on their size or share. For example, if a company makes a profit and distributes it to shareholders, each person gets a portion proportional to how many shares they own. It ensures everyone gets their fair part based on their ownership or stake.
beneficially owned regulatory
"Aggregate amount beneficially owned by each reporting person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"Shared Voting Power"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SGP shares did Vensana distribute?

On November 16, 2026, Vensana Capital I, L.P. made a pro rata distribution of 331,036 shares to Vensana Capital I GP, LLC and its limited partners, without additional consideration. Vensana Capital I GP, LLC then distributed 8,634 shares it received pro rata to its members, also without additional consideration.

What percentage of SGP did the reporting persons beneficially own?

Each of the four reporting persons reported 8.9% beneficial ownership, calculated using 33,461,450 shares outstanding as of November 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





85220G109

(CUSIP Number)
Steven Schwen
3601 W. 76th Street, Suite 20
Edina, MN, 55435
612-217-8680

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/16/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
All shares reported in Rows 7 and 9 are held of record by Vensana GP I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. All shares reported in Rows 8 and 10 are held of record by Vensana I (as defined in Item 2(a) of the Original Schedule 13D (as defined below)). Vensana GP I (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D) outstanding as of November 2, 2026, as set forth in the Issuer's quarterly report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (the "Commission") on November 12, 2026 (the Form "10-Q").


SCHEDULE 13D




Comment for Type of Reporting Person:
All such shares are held of record by Vensana I. Vensana GP I is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock outstanding as of November 2, 2026, as set forth in the Form 10-Q.


SCHEDULE 13D




Comment for Type of Reporting Person:
The shares reported in Rows 7 and 9 consist of (i) 8,372 shares subject to stock options granted to Kirk Nielsen in his capacity as a director of the Issuer that are exercisable as of the date of filing this Amendment (as defined in Item 1 below) or within 60 days thereafter, (ii) 796 shares held of record by the Kirk G. Nielsen Revocable Trust, and (iii) 870 shares held of record by the H17 Trust. Kirk Nielsen is the trustee of the Kirk G. Nielsen Revocable Trust and the Investment Trust Advisor of the H17 Trust and may be deemed to share voting, investment and dispositive power with respect to the securities held by each of the Kirk G. Nielsen Revocable Trust and the H17 Trust. The shares reported in Rows 8 and 10 are held of record by Vensana I. Vensana GP I is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock outstanding as of November 2, 2026, as set forth in the Form 10-Q.


SCHEDULE 13D




Comment for Type of Reporting Person:
The shares reported in Rows 7 and 9 are held of record by Peter Justin Klein directly. The shares reported in Rows 8 and 10 are held of record by Vensana I. Vensana GP I is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock outstanding as of November 2, 2026, as set forth in the Form 10-Q.


SCHEDULE 13D


Vensana Capital I GP, LLC
Signature:/s/ Steven Schwen
Name/Title:Steven Schwen, Chief Financial Officer
Date:11/18/2026
Vensana Capital I, L.P.
Signature:/s/ Steven Schwen
Name/Title:Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC, the general partner of Vensana Capital I, L.P.
Date:11/18/2026
Kirk Nielsen
Signature:/s/ Steven Schwen
Name/Title:Attorney-in-Fact*
Date:11/18/2026
Peter Justin Klein
Signature:/s/ Steven Schwen
Name/Title:Attorney-in-Fact*
Date:11/18/2026
Comments accompanying signature:
*This Amendment was executed pursuant to a Power of Attorney. Note that copies of all applicable Powers of Attorney are already on file with the appropriate agencies.

Keep reading